Inhibitors of SARS-Coronavirus-2 infection
Description of the granted funding
Pharmaceutical interventions to decrease COVID-19 severity and lethality are urgently needed globally. Our multidisciplinary consortium is focused to develop therapies for COVID-19 at University of Helsinki and VTT using different approaches: by cloning and producing human antibodies cloned from individual immune cells from the patients recovered from COVID-19 disease, and by screening safe-in-human compounds for SARS-CoV-2 inhibitory effects in in vitro systems. Structural studies will produce information of SARS-CoV-2 binding at the molecular level, informing also further engineering of the binding antibodies. Animal models of SARS-CoV-2 infection will be developed for further in vivo testing of the inhibitors.
Show moreStarting year
2020
End year
2022
Granted funding
Role in consortium of the Academy of Finland
Partner
Funder
Research Council of Finland
Funding instrument
Targeted Academy projects
Other information
Funding decision number
336495
Fields of science
Plant biology, microbiology, virology
Research fields
Mikrobiologia
Themes
Lisätalousarvio III 2020
Identified topics
covid, pandemic, vaccines